Table 2 |
|||
|
Lipid and plasma fatty acid characteristics of the study participants |
|||
|
LIPID PROFILE |
Pre-treatment |
Post-treatment |
|
|
|
|||
|
Total-C (mmol/L) |
Control |
5.02 ± 0.2 |
5.06 ± 0.2 |
|
Treatment |
4.22 ± 2.3 |
4.21 ± 2.2 |
|
|
LDL-C (mmol/L) |
Control |
3.13 ± 0.2 |
3.10 ± 0.2 |
|
Treatment |
2.42 ± 2.2 |
2.44 ± 2.3 |
|
|
HDL-C (mmol/L) |
Control |
1.39 ± 0.1 |
1.46 ± 0.1 |
|
Treatment |
1.34 ± 0.6 |
1.35 ± 0.7 |
|
|
VLDL-C (mmol/L) |
Control |
0.50 ± 0.0 |
0.51 ± 0.1 |
|
Treatment |
0.46 ± 0.7 |
0.42 ± 0.6 |
|
|
Triacylglycerols (mmol/L)a |
Control |
1.01 ± 0.1 |
1.10 ± 0.3 |
|
Treatment |
1.02 ± 0.2 |
0.91 ± 0.1 b, c |
|
|
FATTY ACID PROFILE |
Pre-treatment |
Post-treatment |
|
|
ALA (umol/L) |
Control |
22.61 ± 3.4 |
20.22 ± 2.1 |
|
Treatment |
23.18 ± 2.3 |
19.74 ± 1.7 |
|
|
AA (umol/L) |
Control |
670.74 ± 60.1 |
696.77 ± 87.1 |
|
Treatment |
599.91 ± 33.9 |
613.12 ± 27.0 |
|
|
DHA (umol/L)a |
Control |
83.23 ± 10.3 |
103.23 ± 15.0 |
|
Treatment |
91.18 ± 9.7 |
125.58 ± 11.9 b, c |
|
|
EPA (umol/L) |
Control |
22.49 ± 3.4 |
20.59 ± 6.8 |
|
Treatment |
17.93 ± 3.1 |
20.77 ± 2.9 |
|
|
|
|||
|
a Significant overall group × time ANCOVA statistical effect (P < 0.01) b Represents a significant within group statistical effect (P < 0.05) c Represents a significant change score different than control (P < 0.05) Total-C (Total cholesterol), LDL-C (low density cholesterol, HDL-C (high density cholesterol), VLDL (very low density cholesterol) ALA (alpha-linolenic acid), AA (arachadonic acid), DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid) |
|||
|
Earnest et al. Journal of the International Society of Sports Nutrition 2009 6:12 doi:10.1186/1550-2783-6-12 |
|||